Critical Appraisal of Amyloid Lowering Agents in AD.

ABSTRACT:

Purpose of review

According to the amyloid cascade hypothesis, removing amyloid beta (Aβ) should cure Alzheimer's disease (AD). In the past three decades, many agents have been tested to try to lower Aβ production, prevent Aβ aggregation, and dissolve Aβ deposits. However, the paucity in definitive preventative or curative properties of these agents in clinical trials has resulted in more avant-garde approaches to therapeutic investigations. Immunotherapy has become an area of focus for research on disease-modifying therapies for neurodegenerative diseases. In this review, we highlight the current clinical development landscape of monoclonal antibody (mAb) therapies that target Aβ plaque formation and removal in AD.

Recent findings

Multiple potential disease-modifying therap

SUBMITTER: Decourt B 

PROVIDER: S-EPMC8192384 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature